MCID: SRS001
MIFTS: 54

Serous Cystadenocarcinoma malady

Cancer category

Summaries for Serous Cystadenocarcinoma

Sources:
8Disease Ontology, 64Wikipedia, 33MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
Disease Ontology:8 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards: Serous Cystadenocarcinoma, also known as serous cystadenocarcinoma, nos, is related to adenocarcinoma and ovarian serous cystadenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is ESR2 (estrogen receptor 2 (ER beta)), and among its related pathways are IL-3 Signaling Pathway and TNF Signaling. The compounds resveratrol and idoxifene have been mentioned in the context of this disorder. Affiliated tissues include lymph node, spleen and colon, and related mouse phenotypes are hearing/vestibular/ear and integument.

Wikipedia:64 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. more...

Aliases & Classifications for Serous Cystadenocarcinoma

Sources:
8Disease Ontology, 10DISEASES, 45Novoseek, 61UMLS, 35MeSH, 57SNOMED-CT, 40NCIt
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer


Aliases & Descriptions:

serous cystadenocarcinoma 8 10
serous cystadenocarcinoma, nos 8
cystadenocarcinoma, serous 61
cystadenocarcinoma serous 45
serous adenocarcinoma 8
serous carcinoma 8


External Ids:

Disease Ontology8 DOID:3114
MeSH35 D018284
SNOMED-CT57 189685001, 90725004

Related Diseases for Serous Cystadenocarcinoma

Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 179)
idRelated DiseaseScoreTop Affiliating Genes
1adenocarcinoma31.3BAX, VEGFA, AKT1, FAS, MUC16, PGR
2ovarian serous cystadenocarcinoma31.3ZNF217, MUC16, USP2, USP14, UBE4A
3papillary carcinoma31.2ESR1, PGR, MUC16
4adenofibroma30.2MUC16
5astrocytoma30.0VEGFA, AKT1
6malignant mixed mullerian tumor30.0PGR, ESR1
7tuberous sclerosis30.0AKT1
8lymphangioleiomyomatosis30.0ESR1, PGR
9papillary cystadenocarcinoma10.8
10pancreatic serous cystadenocarcinoma10.6
11fallopian tube serous adenocarcinoma10.4
12ovarian malignant mesothelioma10.3
13teratoma10.3
14cervical serous adenocarcinoma10.3
15uterine ligament serous adenocarcinoma10.3
16peritoneal serous papillary adenocarcinoma10.3
17malignant peritoneal mesothelioma10.2
18uterine corpus serous adenocarcinoma10.2
19breast adenocarcinoma10.2
20endocervical carcinoma10.1
21neuroendocrine carcinoma10.1
22ovary papillary carcinoma10.1
23large cell carcinoma10.1
24uterine disease10.1
25papillary serous adenocarcinoma10.1
26endosalpingiosis10.1
27ovarian endometriosis10.1
28parovarian cyst10.1
29malignant ovarian cyst10.1
30hypoglycemia10.1
31ovary leiomyosarcoma10.1
32ovarian angiosarcoma10.1
33angiosarcoma10.1
34plasma cell leukemia10.1
35peritoneal carcinoma10.1
36primary peritoneal carcinoma10.1
37cardiac tamponade10.0
38clear cell adenocarcinoma10.0
39cushing's syndrome10.0
40hereditary breast ovarian cancer10.0
41gastric papillary adenocarcinoma10.0
42fallopian tube papillary adenocarcinoma10.0
43verrucous carcinoma10.0
44retroperitoneum carcinoma10.0
45bilateral breast cancer10.0
46wilms tumor10.0
47cerebellar degeneration10.0
48pilocytic astrocytoma10.0
49paraneoplastic cerebellar degeneration10.0
50gastric outlet obstruction10.0

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to serous cystadenocarcinoma

Clinical Features for Serous Cystadenocarcinoma

Drugs & Therapeutics for Serous Cystadenocarcinoma

Sources:
5CenterWatch, 42NIH Clinical Center, 6ClinicalTrials, 61UMLS, 41NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Serous Cystadenocarcinoma

Drug clinical trials:

Search ClinicalTrials for Serous Cystadenocarcinoma

Search NIH Clinical Center for Serous Cystadenocarcinoma

Search CenterWatch for Serous Cystadenocarcinoma

Genetic Tests for Serous Cystadenocarcinoma

Anatomical Context for Serous Cystadenocarcinoma

Sources:
33MalaCards
See all sources

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

33
Lymph node, Spleen, Colon, Liver, Pancreas, Breast, Ovary, Testis

Animal Models for Serous Cystadenocarcinoma or affiliated genes

Sources:
37MGI, 28inGenious Targeting Laboratory
See all sources

Publications for Serous Cystadenocarcinoma

Sources:
51PubMed
See all sources

Articles related to Serous Cystadenocarcinoma:

(show top 50)    (show all 100)
idTitleAuthorsYear
1
Serous papillary cystadenocarcinoma in supernumerary ovary. (23550880)
2013
2
Serous cystadenocarcinoma of pancreas. (23763806)
2013
3
Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. (23040941)
2012
4
Serous cystadenocarcinoma of the pancreas: report of a case and management reflections. (22400805)
2012
5
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. (22066125)
2011
6
A rare case of serous papillary cystadenocarcinoma of the testis. (20133965)
2010
7
Serous cystadenocarcinoma of the pancreas with portal thrombosis. (20499029)
2010
8
Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. (18818939)
2009
9
Peritoneal implantations of papillary serous ovarian cystadenocarcinoma 13 days after initial laparoscopic treatment for a presumed benign ovarian cyst. (19317271)
2009
10
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. (18574502)
2008
11
Macrocystic serous cystadenocarcinoma of the pancreas: the first report of a new pattern of pancreatic carcinoma. (18305183)
2008
12
Plasma cell leukemia with ovarian serous cystadenocarcinoma. (17883177)
2007
13
Immunohistochemical identification of primary peritoneal serous cystadenocarcinoma mimicking advanced colorectal carcinoma: a case report. (18036260)
2007
14
Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. (17553343)
2007
15
ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. (17160949)
2006
16
Primary papillary serous cystadenocarcinoma of broad ligament. (15845057)
2005
17
Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. (16012716)
2005
18
Mean nuclear volume in ovarian papillary serous cystadenocarcinoma. (15032078)
2004
19
A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior. (14551796)
2004
20
Plasma cell leukaemia with papillary serous cystadenocarcinoma of ovary--a case report. (15025299)
2003
21
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. (11201519)
2001
22
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. (11516810)
2001
23
Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. (10886734)
2000
24
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. (9506768)
1998
25
Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary. (9642449)
1998
26
Case report: Serous cystadenocarcinoma of the retroperitoneum: CT and sonographic appearance. (9867279)
1998
27
Serous cystadenocarcinoma and ovarian teratoma during pregnancy. (8737305)
1996
28
Serous cystadenocarcinoma of the pancreas. (8968870)
1996
29
Ovarian-type papillary serous cystadenocarcinoma of the testis. (8653294)
1996
30
Morphologic criteria for the prognosis of serous cystadenocarcinoma of the ovary. (7737584)
1995
31
Lymphadenectomy in stage-III serous cystadenocarcinoma of the ovary. (8745090)
1995
32
Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. (9205465)
1994
33
Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. (8334634)
1993
34
Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. (1427402)
1992
35
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. (2314830)
1990
36
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. (2482644)
1989
37
Parovarian serous cystadenocarcinoma of borderline malignancy diagnosed during pregnancy. (3240895)
1988
38
Simultaneous occurrence of a granulosa cell tumour and a serous papillary cystadenocarcinoma in the same ovary. A case report. (4036607)
1985
39
Serous cystadenocarcinoma as incidental finding during a repeat cesarean section. (4037003)
1985
40
Cytogenetics of a cell line derived from an ovarian papillary serous cystadenocarcinoma. (6744227)
1984
41
Serous papillary cystadenocarcinoma associated with alpha-fetoprotein production. (6205636)
1984
42
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. (6206939)
1984
43
Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. (6583437)
1984
44
Occurrence of bone in serous cystadenocarcinoma of the ovary. (6816209)
1982
45
Nature of carcinoembryonic antigen purified from malignant ascitic fluid of serous cystadenocarcinoma of the ovary. (7300840)
1981
46
Ultrasonic diagnosis of serous cystadenocarcinoma of the ovary. (874359)
1977
47
Antigenicity of papillary serous cystadenocarcinoma tissue culture cells. (4970936)
1968
48
COEXISTENT BILATERAL PAPILLARY SEROUS CYSTADENOCARCINOMA AND BILATERAL BENIGN CYSTIC TERATOMA IN PREGNANCY. REPORT OF A CASE. (14211024)
1964
49
Serous cystadenocarcinoma of ovary, bilateral, stage II, six-year survival. A case report. (13981334)
1963
50
Serous cystadenocarcinoma of the ovary; a review of 127 cases. (13056935)
1953

Genetic Variations for Serous Cystadenocarcinoma

Expression for genes affiliated with Serous Cystadenocarcinoma

Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Serous Cystadenocarcinoma.

Pathways for genes affiliated with Serous Cystadenocarcinoma

Sources:
38NCBI BioSystems Database, 56SinoBiological, 53R&D Systems, 54Reactome, 52QIAGEN, 50PharmGKB, 12EMD Millipore, 30KEGG, 4Cell Signaling Technology
See all sources

Pathways related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 31)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.3BIRC5
2
Hide members
10.3AKT1
310.0ESR2, PGR, CYP19A1
49.9BCL2, BIRC5, AKT1
59.9ESR2, ESR1, AKT1
69.9ESR2, ESR1, AKT1
7
Hide members
9.9ESR2, ESR1, PGR
89.9BCL2, BAX, AKT1
9
Hide members
9.9AKT1, BAX, BCL2
10
Hide members
9.9AKT1, BAX, BCL2
119.9AKT1, BAX, BCL2
12
Hide members
9.9ESR2, ESR1, CYP19A1
139.9BCL2, BAX, FAS
149.9BCL2, ESR1, AKT1
15
Hide members
9.8BCL2, BIRC5, BAX, AKT1
169.7FAS, BAX, BIRC5, BCL2
17
Apoptosis and survival Apoptotic TNF-family pathways
Hide members
9.7BCL2, BIRC5, BAX, FAS
18
Apoptosis and survival Caspase cascade
Hide members
9.7FAS, AKT1, BAX, BCL2
19
Hide members
9.7FAS, AKT1, BAX, BCL2
20
Apoptosis and survival Anti-apoptotic action of nuclear ESR1 and ESR2
Hide members
9.7BAX, ESR1, ESR2, BCL2
21
Development Endothelin-1/EDNRA signaling
Hide members
9.7AKT1, VEGFA, ESR1, ESR2
229.7ESR1, VEGFA, AKT1, FAS
23
Hide members
9.6FAS, AKT1, BAX, BIRC5, BCL2
24
Hide members
9.6FAS, AKT1, BAX, BIRC5, BCL2
25
Development Prolactin receptor signaling
Hide members
9.6AKT1, BAX, ESR1, ESR2, BCL2
269.4AKT1, AMY1A, AMY1B, AMY1C
27
Hide members
9.4AMY1C, AMY1B, AMY1A, CYP19A1
289.4FAS, AKT1, VEGFA, BAX, BIRC5, BCL2
29
Hide members
9.3FAS, AKT1, VEGFA, BAX, ESR1, BCL2
309.3AKT1, VEGFA, BAX, CYP19A1, ESR1, BCL2
319.2BCL2, FAS, AKT1, VEGFA, BAX, ESR1

Compounds for genes affiliated with Serous Cystadenocarcinoma

Sources:
45Novoseek, 60Tocris Bioscience, 11DrugBank, 24HMDB, 50PharmGKB, 29IUPHAR, 2BitterDB
See all sources

Compounds related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 195)
idCompoundScoreTop Affiliating Genes
1resveratrol45 60 11 2413.7PGR
2idoxifene4510.2CYP19A1, ESR1, PGR
3ponicidin4510.2BAX, BIRC5, BCL2
4estradiol benzoate4510.1PGR, ESR1, CYP19A1, ESR2
5nandrolone45 2411.1CYP19A1, PGR, ESR1, ESR2
6leuprolide acetate4510.1CYP19A1, PGR, ESR1, ESR2
7exemestane50 45 60 1113.1ESR1, PGR, CYP19A1, ESR2
8bisphenol a4510.1CYP19A1, PGR, ESR1, ESR2
9tanshinone iia4510.1FAS, BCL2, BAX
10lapatinib45 50 1112.1BIRC5, ESR1, PGR, CYP19A1
113,3-diindolylmethane4510.1VEGFA, BIRC5, ESR1, BAX
12clomiphene citrate4510.1PGR, ESR1, CYP19A1, ESR2
13hoechst 333424510.0FAS, BIRC5, BAX, BCL2
14fulvestrant45 50 29 1113.0PGR, ESR1, ESR2, CYP19A1
155fluorouracil4510.0FAS, BAX, PGR, BCL2, BIRC5
16letrozole45 50 60 1113.0CYP19A1, PGR, ESR2, ESR1
17toremifene45 1111.0CYP19A1, PGR, ESR1, ESR2, FAS
18levonorgestrel45 60 29 1113.0ESR2, ESR1, CYP19A1, PGR
194-hydroxytamoxifen459.9CYP19A1, ESR1, PGR, AKT1, ESR2
20noxa459.9BIRC5, BCL2, BAX, FAS
21indole-3-carbinol459.8BAX, AKT1, CYP19A1, BIRC5, ESR1, BCL2
22adriamycin459.8BIRC5, BCL2, PGR, BAX, AKT1, FAS
23gefitinib45 50 1111.8ESR1, CYP19A1, VEGFA, AKT1, BIRC5, ESR2
24celecoxib45 60 29 50 11 2414.8VEGFA, BAX, AKT1, CYP19A1, BCL2, BIRC5
25progestin459.8VEGFA, ESR1, PGR, CYP19A1, ESR2
26thymidylate459.8BIRC5, BAX, VEGFA, ESR2, FAS, BCL2
27taxane459.8VEGFA, CYP19A1, PGR, BIRC5, BCL2, ESR1
28gemcitabine45 50 1111.7BCL2, CYP19A1, BAX, VEGFA, AKT1, BIRC5
29trastuzumab45 50 1111.7BIRC5, ESR1, CYP19A1, VEGFA, PGR, FAS
30steroidal459.7ESR2, CYP19A1, ESR1, PGR
31etoposide45 50 60 1112.7BAX, ESR2, AKT1, FAS, BCL2
32dexamethasone45 50 29 1112.7FAS, BCL2, BIRC5, MUC16, VEGFA, AKT1
332-chlorodeoxyadenosine459.6FAS, BAX, BIRC5, BCL2
34mifepristone45 60 29 1112.6VEGFA, BAX, CYP19A1, PGR, BIRC5, ESR2
35arsenite45 2410.6FAS, VEGFA, BAX, AKT1, BCL2, BIRC5
36mg 13245 6010.6BIRC5, AKT1, ESR1, VEGFA, BAX, FAS
37docetaxel45 50 60 1112.6CYP19A1, PGR, BIRC5, VEGFA, BAX, BCL2
38ly294002459.5ESR1, BAX, VEGFA, AKT1, FAS, BIRC5
39actinomycin d459.4BCL2, ESR1, BIRC5, BAX, VEGFA, AKT1
40sb 20358045 6010.4BCL2, BAX, BIRC5, FAS, VEGFA, AKT1
41testosterone45 60 11 2412.3ESR2, AKT1, MUC16, CYP19A1, PGR, BIRC5
42cisplatin45 50 60 1112.2BCL2, BIRC5, MUC16, BAX, VEGFA, AKT1
43tamoxifen45 50 29 1112.1BCL2, ESR2, FAS, AKT1, VEGFA, CYP19A1
44genistein45 29 60 2 11 2414.1ESR2, BCL2, FAS, AKT1, VEGFA, BAX
45n acetylcysteine459.1BCL2, BIRC5, BAX, AKT1, FAS, VEGFA
46retinoic acid45 2410.0BIRC5, FAS, ESR2, AKT1, ESR1, PGR
47paraffin459.0AKT1, FAS, BAX, MUC16, PGR, VEGFA
48vegf459.0FAS, BCL2, ESR2, ESR1, BIRC5, PGR
49paclitaxel45 50 1111.0MUC16, FAS, BIRC5, BCL2, AKT1, BAX
50doxorubicin45 50 1110.8BCL2, VEGFA, PGR, ESR1, FAS, CYP19A1

GO Terms for genes affiliated with Serous Cystadenocarcinoma

Sources:
16Gene Ontology
See all sources

Cellular components related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:04693010.1BCL2, BAX

Biological processes related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 19)
idNameGO IDScoreTop Affiliating Genes
1regulation of nitrogen utilizationGO:00680810.4BAX, BCL2
2renal system processGO:00301410.4BCL2, FAS
3activation-induced cell death of T cellsGO:00692410.4AKT1, FAS
4regulation of protein heterodimerization activityGO:04349710.3BAX, BCL2
5regulation of protein homodimerization activityGO:04349610.3BAX, BCL2
6transformed cell apoptotic processGO:00692710.3FAS, BAX
7vagina developmentGO:06006810.3ESR2, ESR1, BAX
8neuron apoptotic processGO:05140210.2BCL2, BAX, FAS
9intrinsic apoptotic signaling pathwayGO:09719310.2BCL2, BAX, AKT1
10uterus developmentGO:06006510.2ESR1, ESR2
11positive regulation of peptidyl-serine phosphorylationGO:03313810.2AKT1, VEGFA, BCL2
12negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:04315410.2AKT1, VEGFA, BIRC5
13positive regulation of nitric-oxide synthase activityGO:05100010.1ESR1, AKT1
14response to toxic substanceGO:00963610.1BCL2, BAX, FAS
15ovarian follicle developmentGO:00154110.0BCL2, ESR2, BAX, VEGFA
16positive regulation of sequence-specific DNA binding transcription factor activityGO:0510919.9ESR2, ESR1, AKT1
17response to acidGO:0011019.8BCL2, BAX
18positive regulation of apoptotic processGO:0430659.7FAS, AKT1, BAX, ESR2
19negative regulation of apoptotic processGO:0430669.7FAS, AKT1, VEGFA, BIRC5, BCL2

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1estrogen response element bindingGO:03405610.3ESR2, ESR1
2BH3 domain bindingGO:05143410.2BCL2, BAX
3steroid bindingGO:00549610.1PGR, ESR1, ESR2
4estrogen receptor activityGO:03028410.1ESR1, ESR2
5core promoter sequence-specific DNA bindingGO:00104610.1ESR2, ESR1
6steroid hormone receptor activityGO:00370710.0ESR2, ESR1, PGR
7nitric-oxide synthase regulator activityGO:03023510.0ESR1, AKT1
8enzyme bindingGO:0198999.8ESR2, ESR1, BIRC5, PGR, AKT1
9channel activityGO:0152679.8BCL2, BAX
10identical protein bindingGO:0428029.1BCL2, FAS, USP2, AKT1, VEGFA, BAX
11protein bindingGO:0055157.0VEGFA, AKT1, USP2, USP14, FAS, UBE4A

Products for genes affiliated with Serous Cystadenocarcinoma

  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Serous Cystadenocarcinoma

3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet